在对下一代癌症疗法投资不断增加的背景下，溶瘤病毒癌症治疗市场预计在预测期（2026-2036年）内将迅速扩张 DelveInsight-动脉网

Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight

CISION 等信源发布 2026-08-26 22:41



可切换为仅中文







The oncolytic virus cancer therapy market is poised for significant growth, driven by increasing research and development of genetically engineered viruses that selectively target and destroy cancer cells while stimulating anti-tumor immune responses. The expanding clinical pipeline of therapies such as Cretostimogene grenadenorepvec (CG Oncology), CAN-2409 (Candel Therapeutics), AdAPT-001 (EpicentRx), LOAd703 (Lokon Pharma), RP1 (Replimune), VG 161 (Virogin Biotech), RP2 (Replimune), and others are expected to further accelerate market growth..

溶瘤病毒癌症治疗市场有望实现显著增长，其驱动力在于针对基因工程病毒的研發日益增加，这些病毒能够选择性靶向并摧毁癌细胞，同时激发抗肿瘤免疫反应。随着Cretostimogene grenadenorepvec（CG Oncology公司）、CAN-2409（Candel Therapeutics公司）、AdAPT-001（EpicentRx公司）、LOAd703（Lokon Pharma公司）、RP1（Replimune公司）、VG 161（Virogin Biotech公司）、RP2（Replimune公司）等疗法临床管线的不断扩展，预计将进一步加速市场增长。

LAS VEGAS

拉斯维加斯

，

Aug. 26, 2026

2026年8月26日

/PRNewswire/ -- DelveInsight's Oncolytic Virus Cancer Therapy Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Melanoma, Biliary Tract Cancer, Head and Neck Cancer, Pancreatic Cancer, NSCLC, Hepatocellular Carcinoma, Breast Cancer, Prostate Cancer, Brain Cancer, Bladder Cancer, Ovarian Cancer, and others.

/PRNewswire/ -- DelveInsight的《溶瘤病毒癌症治疗市场规模、目标人群、竞争格局与市场预测》报告全面剖析了当前的治疗实践和可覆盖的患者人群，涵盖黑色素瘤、胆道癌、头颈癌、胰腺癌、非小细胞肺癌、肝细胞癌、乳腺癌、前列腺癌、脑癌、膀胱癌、卵巢癌等主要适应症及其他适应症。

The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging oncolytic virus cancer therapy, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets (the US, EU4, UK, and Japan)..

所选适应症基于已获批的疗法和正在进行的研发管线活动。报告还提供了对新兴溶瘤病毒癌症疗法的洞察、各疗法的市场份额，以及2022年至2036年期间当前和预测的市场规模，并按领先市场（美国、欧盟四国、英国和日本）进行细分。

Key Takeaways from the Oncolytic Virus Cancer Therapy Market Report

溶瘤病毒癌症治疗市场报告的关键要点

The market size for oncolytic virus cancer therapy was found to be

溶瘤病毒癌症疗法的市场规模被发现为

USD 177 million

1.77亿美元

in the 7MM in 2025.

在2025年的7MM中。

The United States accounted for the largest oncolytic virus immunotherapy market size of the total market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

2025年，在七大主要市场（7MM）中，美国占溶瘤病毒免疫疗法市场规模的份额最大，高于其他主要市场，包括欧盟四国（德国、法国、意大利和西班牙）、英国和日本。

The report provides the total potential number of patients in the indications, such as

该报告提供了各适应症中潜在患者总数，例如

Melanoma, Biliary Tract Cancer, Head and Neck Cancer, Pancreatic Cancer, NSCLC, Hepatocellular Carcinoma, Breast Cancer, Prostate Cancer, Brain Cancer, Bladder Cancer, Ovarian Cancer, and others

黑色素瘤、胆道癌、头颈癌、胰腺癌、非小细胞肺癌、肝细胞癌、乳腺癌、前列腺癌、脑癌、膀胱癌、卵巢癌等

。

Oncolytic virus therapies are primarily being developed to treat cancers in relapsed refractory settings. Consequently, these therapies could address nearly

溶瘤病毒疗法主要正在被开发用于治疗复发难治性癌症。因此，这些疗法可以解决几乎

20%

百分之二十

of all cancer cases, providing a significant treatable patient pool.

占所有癌症病例的很大一部分，提供了可观的可治疗患者群体。

Leading oncolytic virus companies, such as

领先的溶瘤病毒公司，例如

CG Oncology, Candel Therapeutics, EpicentRx, Lokon Pharma, Replimune, Virogin Biotech, Binhui Bio, Genelux, Imugene, BioInvent, Transgene, Oncolytics Biotech,

CG Oncology、Candel Therapeutics、EpicentRx、Lokon Pharma、Replimune、Virogin Biotech、滨会生物、Genelux、Imugene、BioInvent、Transgene、Oncolytics Biotech，

and others, are developing novel oncolytic virus cancer therapies that can be available in the oncolytic virus therapy market in the coming years.

以及其他机构正在开发新型溶瘤病毒癌症疗法，这些疗法有望在未来几年内进入溶瘤病毒治疗市场。

Some of the key oncolytic virus cancer therapies in clinical trials include

临床试验中一些关键的溶瘤病毒癌症疗法包括

Cretostimogene grenadenorepvec, CAN-2409, AdAPT-001, LOAd703, RP1, RP2, VG 161, BS001, Olvi-Vec, CF33, BT-001, TG6050, Pelareorep,

Cretostimogene grenadenorepvec、CAN-2409、AdAPT-001、LOAd703、RP1、RP2、VG 161、BS001、Olvi-Vec、CF33、BT-001、TG6050、Pelareorep，

and others.

以及其他。

Discover real-time oncolytic virus analysis @

发现实时溶瘤病毒分析 @

https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market

Key Factors Driving the Oncolytic Virus Cancer Therapy Market

推动溶瘤病毒癌症治疗市场的关键因素

Growing Adoption of Novel Cancer Immunotherapies:

新型癌症免疫疗法的日益普及：

The increasing shift toward innovative immuno-oncology approaches is driving interest in oncolytic virus therapies. These treatments can selectively infect and destroy tumor cells while also stimulating broader antitumor immune responses.

日益向创新免疫肿瘤学方法的转变，正推动人们对溶瘤病毒疗法的兴趣。这些疗法能够选择性感染并摧毁肿瘤细胞，同时激发更广泛的抗肿瘤免疫反应。

Rising Cancer Burden Worldwide:

全球癌症负担日益加重：

The growing incidence of cancer and the need for more effective treatment options are creating demand for alternative therapeutic modalities. Oncolytic viruses offer a promising approach, particularly for patients with advanced or treatment-resistant cancers.

癌症发病率的不断上升以及对更有效治疗方案的需求，正在推动对替代性治疗方式的需求。溶瘤病毒提供了一种颇具前景的治疗途径，尤其适用于晚期或耐药性癌症患者。

Advancements in Viral Engineering Technologies:

病毒工程技术进展：

Progress in genetic engineering is enabling the development of more targeted and potent oncolytic viruses. Researchers can modify viral platforms to improve tumor selectivity, enhance immune activation, and deliver therapeutic genes directly to cancer cells.

基因工程的进步使得开发更具靶向性和更强效的溶瘤病毒成为可能。研究人员可以对病毒平台进行改造，以提高肿瘤选择性、增强免疫激活，并将治疗基因直接递送至癌细胞。

Increasing Clinical Development and Pipeline Activity:

临床开发及管线活动日益增加：

Pharmaceutical and biotechnology companies are expanding their oncolytic virus therapy pipelines across multiple tumor types. Growing clinical trial activity of therapies such as

制药和生物技术公司正在扩展其溶瘤病毒疗法在多种肿瘤类型中的研发管线。诸如以下疗法的临床试验活动日益增多：

Cretostimogene grenadenorepvec

克雷托刺激基因格瑞纳多诺普维克

(CG Oncology),

CAN-2409

(Candel Therapeutics),

（Candel Therapeutics）

AdAPT-001

(EpicentRx),

（EpicentRx）

LOAd703

(Lokon Pharma),

（Lokon Pharma）

RP1

(Replimune),

（Replimune），

VG 161

(Virogin Biotech), and others, and encouraging efficacy data are supporting greater investment and market interest.

（Virogin Biotech）等公司，以及令人鼓舞的疗效数据正推动着更多的投资和市场关注。

Aparna Thakur, an oncology expert at DelveInsight, said that with ongoing advancements and strategic collaborations, oncolytic viruses are positioned to play a pivotal role in the future of oncology, providing patients with new hope and facilitating the development of more effective and personalized cancer therapies..

DelveInsight 的肿瘤学专家阿帕尔纳·塔库尔（Aparna Thakur）表示，随着持续的技术进步和战略合作，溶瘤病毒有望在肿瘤学的未来发展中发挥关键作用，为患者带来新希望，并推动更有效、更个性化的癌症疗法的开发。

Oncolytic Virus Cancer Therapy Market Analysis

溶瘤病毒癌症治疗市场分析报告

Oncolytic viruses represent a promising immunotherapeutic approach in which viruses are used to selectively infect and eliminate cancer cells. Beyond their inherent tumor-targeting properties, these viruses can be genetically engineered to introduce therapeutic genes into malignant cells, thereby enhancing their antitumor activity..

溶瘤病毒代表了一种前景广阔的免疫治疗方法，通过利用病毒选择性感染并清除癌细胞。除了其固有的肿瘤靶向特性外，这些病毒还可以通过基因工程改造，将治疗性基因导入恶性肿瘤细胞，从而增强其抗肿瘤活性。

In 2015,

2015年，

IMLYGIC

became the first oncolytic virus to receive U.S. FDA approval for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma that had recurred following initial surgery.

成为首个获得美国食品药品监督管理局（FDA）批准、用于局部治疗初治手术后复发的黑色素瘤患者不可切除的皮肤、皮下及淋巴结病变的溶瘤病毒。

Subsequently, in June 2021,

随后，在2021年6月，

DELYTACT

德立他克

(teserpaturev/G47∆; Daiichi Sankyo) obtained conditional and time-limited approval from Japan's Ministry of Health, Labor and Welfare (MHLW) for the treatment of patients with malignant glioma.

(teserpaturev/G47∆；第一三共) 获得了日本厚生劳动省（MHLW）针对恶性胶质瘤患者治疗的有条件且限时批准。

A diverse range of oncolytic virus platforms is currently being investigated in clinical development, including adenoviruses, herpes simplex viruses, Maraba viruses, measles viruses, Newcastle disease viruses, picornaviruses, reoviruses, vaccinia viruses, vesicular stomatitis viruses, and other viral platforms..

目前，多种溶瘤病毒平台正处于临床开发研究阶段，包括腺病毒、单纯疱疹病毒、马拉巴病毒、麻疹病毒、新城疫病毒、小核糖核酸病毒、呼肠孤病毒、痘苗病毒、水疱性口炎病毒以及其他病毒平台。

Encouraging clinical trial outcomes across multiple cancer types, including melanoma, bladder cancer, biliary tract cancer (BTC), glioblastoma, ovarian cancer, pancreatic cancer, and other solid tumors, have further accelerated interest in and development of these emerging therapeutic modalities.

在包括黑色素瘤、膀胱癌、胆道癌（BTC）、胶质母细胞瘤、卵巢癌、胰腺癌及其他实体瘤在内的多种癌症类型中，临床试验结果令人鼓舞，进一步加速了人们对这些新兴治疗模式的兴趣及其开发进程。

As a result, the oncolytic virus therapy (OVT) pipeline is expanding rapidly, with companies such as

因此，溶瘤病毒疗法（OVT）的研发管线正在迅速扩张，诸如

Genelux

(Olvi-Vec),

（奥尔维-维克）

Candel Therapeutics

坎德尔治疗公司

(CAN-2409),

CG Oncology

CG肿瘤学

(cretostimogene grenadenorepvec),

（克雷托刺激基因格雷纳多雷普维克）

Oncolytics Biotech

(pelareorep),

（佩拉雷奥雷普）

Replimune

(RP1),

(RP1)，

Lokon Pharma

洛康制药

(LoAd703),

Imugene

伊姆基因

(CF33), and

(CF33)，以及

SillaJen

希拉珍

(Pexa-Vec [JX-594]) advancing candidates through clinical development.

(Pexa-Vec [JX-594]) 推进候选药物通过临床开发。

In parallel, SillaJen is progressing next-generation oncolytic immunotherapy candidates, including the SJ-600 and JX-900 series, further highlighting ongoing efforts to develop innovative virus-based treatments for cancer.

与此同时，SillaJen 正在推进下一代溶瘤免疫疗法候选药物（包括 SJ-600 和 JX-900 系列）的研发，进一步凸显了其在开发创新型病毒基癌症治疗手段方面的持续努力。

Learn more about the hydroxychloroquine oncolytic virus cancer therapy @

了解更多关于羟氯喹溶瘤病毒癌症疗法的信息 @

Oncolytic Virus Analytics

溶瘤病毒分析

Oncolytic Virus Cancer Therapy Competitive Landscape

溶瘤病毒癌症治疗竞争格局

Some of the oncolytic viruses under development include

正在开发的一些溶瘤病毒包括

Cretostimogene grenadenorepvec

克雷托刺激基因格雷纳登诺雷普韦克

(CG Oncology),

（CG Oncology）

CAN-2409

(Candel Therapeutics),

AdAPT-001

(EpicentRx),

(EpicentRx)

LOAd703

(Lokon Pharma),

（洛康制药）

RP1

(Replimune),

VG 161

(Virogin Biotech),

（Virogin Biotech），

RP2

(Replimune),

BS001

(Binhui Bio),

（滨辉生物）

Olvi-Vec

奥尔维-维克

(Genelux),

（Genelux）

CF33

(Imugene),

（Imugene）

BT-001

(BioInvent/Transgene),

TG6050

(Transgene),

（转基因）

Pelareorep

佩拉雷奥普

(Oncolytics Biotech), and others.

（Oncolytics Biotech）等。

Genelux's

Genelux的

Olvi-Vec

奥尔维-维克

is a genetically modified vaccinia virus with a triple mechanism of action. It directly targets and destroys cancer cells, activates a tumor-specific immune response, and transforms the tumor microenvironment from an immunosuppressive 'cold' state into an immunoreactive 'hot' state. The therapy is currently under clinical development for several cancers, including platinum-resistant/refractory ovarian cancer, recurrent non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and pancreatic cancer.

是一种具有三重作用机制的基因改造痘苗病毒。它可直接靶向并摧毁癌细胞，激活肿瘤特异性免疫反应，并将肿瘤微环境从免疫抑制性的“冷”状态转化为免疫反应性的“热”状态。该疗法目前正处于针对多种癌症的临床开发阶段，包括铂类耐药/难治性卵巢癌、复发性非小细胞肺癌（NSCLC）、小细胞肺癌（SCLC）以及胰腺癌。

In November 2023, Genelux announced that the US FDA had granted .

2023年11月，Genelux宣布美国食品药品监督管理局（FDA）已授予。

Fast Track Designation (FTD)

快速通道认定（FTD）

to olvi-vec for its development in patients with platinum-resistant/refractory ovarian cancer.

用于其在铂类耐药/难治性卵巢癌患者中的开发。

CG Oncology's Cretostimogene

CG Oncology 的 Cretostimogene

is an investigational oncolytic immunotherapy administered intravesically and is being studied in the

是一种经膀胱内给药的在研溶瘤免疫疗法，目前正在研究中

Phase III BOND-003 trial

BOND-003 三期临床试验

for patients with Bacillus Calmette–Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). It is also being evaluated as a monotherapy in the Phase III PIVOT-006 trial for patients with intermediate-risk NMIBC. The US FDA has granted both

适用于对卡介苗（BCG）无反应的非肌层浸润性膀胱癌（NMIBC）患者。该药物还在针对中危NMIBC患者的III期PIVOT-006试验中作为单药疗法进行评估。美国食品药品监督管理局（FDA）已授予两者

Fast Track Designation (FTD) and Breakthrough Therapy Designation (BTD)

快速通道认定（FTD）和突破性疗法认定（BTD）

to cretostimogene grenadenorepvec for the treatment of high-risk, BCG-unresponsive NMIBC with carcinoma in situ, with or without Ta or T1 papillary tumors.

用于克雷托斯替莫金（cretostimogene）grenadenorepvec 治疗伴有或不伴有 Ta 或 T1 期乳头状肿瘤的、对卡介苗（BCG）无反应的高风险非肌层浸润性膀胱癌（NMIBC），且合并原位癌。

BioInvent/Transgene's BT-001

BioInvent/Transgene 的 BT-001

is a drug candidate being developed through a collaboration with French biotechnology company Transgene. It is an oncolytic virus engineered to deliver BioInvent's anti-CTLA-4 antibody directly within tumors. By releasing the antibody locally as the virus infects tumor cells, BT-001 is designed to enhance tumor-targeted activity while potentially reducing systemic side effects.

BT-001 是一种正在与法国生物技术公司 Transgene 合作开发的候选药物。它是一种经过工程改造的溶瘤病毒，旨在将 BioInvent 的抗 CTLA-4 抗体直接递送至肿瘤内部。通过在病毒感染肿瘤细胞时局部释放抗体，BT-001 旨在增强针对肿瘤的活性，同时可能降低全身性副作用。

The candidate is currently being investigated in combination with pembrolizumab in a Phase 1/2a clinical trial..

该候选药物正在一项1/2a期临床试验中与帕博利珠单抗联合接受调查。

The anticipated launch of these emerging therapies are poised to transform the oncolytic virus market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the oncolytic virus cancer therapy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth..

这些新兴疗法的预期推出，有望在未来几年重塑溶瘤病毒市场的格局。随着这些前沿疗法不断成熟并获得监管批准，预计将重构溶瘤病毒癌症治疗市场的格局，树立新的护理标准，并为医疗创新和经济增长开辟机遇。

To know more about oncolytic virus therapies developers companies, visit @

如需了解更多关于溶瘤病毒疗法开发公司的信息，请访问 @

Oncolytic Virus Landscape

溶瘤病毒格局

Recent Developments in the Oncolytic Virus Cancer Therapy Market

溶瘤病毒癌症治疗市场的最新进展

在

August 2026, Replimune Group, Inc.

2026年8月，Replimune Group, Inc.

announced that the FDA has granted accelerated approval to TUDRIQEVTM (vusolimogene oderparepvec-wtpg), formerly known as RP1, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease has progressed following treatment with an anti-PD-1 antibody-based regimen..

宣布美国食品药品监督管理局（FDA）已加速批准TUDRIQEVTM（vusolimogene oderparepvec-wtpg，前称RP1）联合纳武利尤单抗，用于接受抗PD-1抗体方案治疗后疾病进展的不可切除晚期皮肤黑色素瘤成人患者。

在

July 2026, UroGen Pharma Ltd.

2026年7月，UroGen Pharma有限公司

announced that the FDA has cleared its Investigational New Drug (IND) application for UGN-501, a next-generation investigational oncolytic virus. The IND clearance paves the way for the initiation of a planned Phase 1 clinical trial evaluating UGN-501 in patients with non-muscle invasive bladder cancer (NMIBC)..

宣布美国食品药品监督管理局（FDA）已批准其新一代在研溶瘤病毒UGN-501的新药临床试验（IND）申请。该IND获批为启动计划中的1期临床试验铺平了道路，该试验旨在评估UGN-501在非肌层浸润性膀胱癌（NMIBC）患者中的疗效和安全性。

在

June 2026, Candel Therapeutics, Inc.

2026年6月，Candel Therapeutics, Inc.

initiated the global pivotal Phase 3 AURORA trial (NCT07660094) to evaluate aglatimagene besadenovec (aglatimagene; CAN-2409) plus valacyclovir alongside continued pembrolizumab treatment in patients with metastatic non-squamous NSCLC who experienced disease progression following pembrolizumab and platinum-based chemotherapy..

启动了全球关键性III期AURORA试验（NCT07660094），以评估在既往接受帕博利珠单抗和含铂化疗后出现疾病进展的转移性非鳞状非小细胞肺癌患者中，阿格拉蒂马基因贝沙德诺韦（阿格拉蒂马基因；CAN-2409）联合伐昔洛韦并继续帕博利珠单抗治疗的疗效。

在

May 2026, CG Oncology

2026年5月，CG Oncology

reported positive Phase II CORE-008 Cohort CX results, with cretostimogene grenadenorepvec plus gemcitabine demonstrating encouraging high-grade event-free survival (HG-EFS), high complete response (CR) rates, and favorable tolerability in high-risk NMIBC patients. The data, which demonstrate encouraging HG-EFS, high CR rates, and a well-tolerated safety profile, were presented at the Society of Urologic Oncology (SUO) Session at the 2026 American Urological Association (AUA) Annual Meeting..

报告了CORE-008研究CX队列的阳性II期结果，在高风险非肌层浸润性膀胱癌（NMIBC）患者中，cretostimogene grenadenorepvec联合吉西他滨显示出令人鼓舞的高级别无事件生存率（HG-EFS）、较高的完全缓解（CR）率以及良好的耐受性。这些数据展现了令人鼓舞的HG-EFS、高CR率以及良好的安全性特征，并在2026年美国泌尿协会（AUA）年会的泌尿肿瘤学会（SUO）专场上发表。

在

March 2026, Genelux

2026年3月，Genelux

reported positive clinical progress for Olvi-Vec, with Phase III ovarian cancer topline data expected in 2H26, encouraging lung cancer results, and cash runway extending into 1Q27.

报告称Olvi-Vec取得积极的临床进展，预计2026年下半年公布III期卵巢癌试验的顶线数据，肺癌试验结果令人鼓舞，现金跑道延长至2027年第一季度。

在

February 2026, CG Oncology

2026年2月，CG Oncology

reported accelerated enrollment and an expedited Phase III (PIVOT-006) timeline in intermediate-risk NMIBC, with topline data expected in 1H26. The company also reported strong efficacy and durability data for cretostimogene across high-risk NMIBC cohorts, announced upcoming Phase II combination results with gemcitabine, and remains on track for a BLA submission in high-risk BCG-unresponsive NMIBC during 2026..

报告称，在中危非肌层浸润性膀胱癌（NMIBC）患者中，入组加速，III期临床试验（PIVOT-006）时间线提前，预计2026年上半年公布主要数据。该公司还报告了cretostimogene在高危NMIBC各队列中的强劲疗效和持久性数据，宣布即将公布与吉西他滨联合使用的II期临床试验结果，并计划在2026年提交针对高危BCG无应答NMIBC的生物制品许可申请（BLA），目前进展顺利。

Oncolytic Virus Cancer Therapy Epidemiology Segmentation

溶瘤病毒癌症疗法的流行病学细分

The oncolytic virus market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2022–2036 across the leading markets. Effective therapies for gastrointestinal cancers are scarce, with less than

溶瘤病毒市场报告是一份全面且专业的分析，为2022–2036年研究期间的主要市场提供深入的流行病学见解。胃肠道癌症的有效疗法稀缺，不足

12%

百分之十二

of pancreatic cancer patients surviving beyond five years with the current standard of care.

在当前标准治疗方案下，胰腺癌患者生存期超过五年的比例。

The oncolytic virus cancer therapy target patient pool is segmented into:

溶瘤病毒癌症疗法的目标患者群体细分为：

Total Cases of Selected Cancer Types

选定癌症类型的总病例数

Target Patient Pool of OVTs by Cancer Types

按癌症类型划分的溶瘤病毒（OVT）目标患者池

Treated Cases by Cancer Types

按癌症类型分类的治疗病例

Oncolytic Virus Cancer Therapy Report Metrics

溶瘤病毒癌症治疗报告指标

Details

详情

Study Period

学习周期

2022–2036

Oncolytic Virus Cancer Therapy Report Coverage

溶瘤病毒癌症治疗报告覆盖范围

7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

7MM [美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本]

Key Indications Covered in the Report

报告中涵盖的关键适应症

Melanoma, Biliary Tract Cancer, Head and Neck Cancer, Pancreatic Cancer, NSCLC, Hepatocellular Carcinoma, Breast Cancer, Prostate Cancer, Brain Cancer, Bladder Cancer, Ovarian Cancer, and others

黑色素瘤、胆道癌、头颈癌、胰腺癌、非小细胞肺癌、肝细胞癌、乳腺癌、前列腺癌、脑癌、膀胱癌、卵巢癌及其他

Oncolytic Virus Therapies Market Size in 2025

2025年溶瘤病毒疗法市场规模

USD 177 Million

1.77亿美元

Key Oncolytic Virus Companies

主要溶瘤病毒公司

CG Oncology, Candel Therapeutics, EpicentRx, Lokon Pharma, Replimune, Virogin Biotech, Binhui Bio, Genelux, Imugene, BioInvent, Transgene, Oncolytics Biotech, Amgen, Daiichi Sankyo, and others

CG Oncology、Candel Therapeutics、EpicentRx、Lokon Pharma、Replimune、Virogin Biotech、宾会生物、Genelux、Imugene、BioInvent、Transgene、Oncolytics Biotech、安进、第一三共及其他公司

Key Oncolytic Virus Cancer Therapy

关键溶瘤病毒癌症疗法

Cretostimogene grenadenorepvec, CAN-2409, AdAPT-001, LOAd703, RP1, RP2, VG 161, BS001, Olvi-Vec, CF33, BT-001, TG6050, Pelareorep, IMLYGIC, DELYTACT, and others

Cretostimogene grenadenorepvec、CAN-2409、AdAPT-001、LOAd703、RP1、RP2、VG 161、BS001、Olvi-Vec、CF33、BT-001、TG6050、Pelareorep、IMLYGIC、DELYTACT 等

Scope of the

的范围

Oncolytic Virus Cancer Therapy

溶瘤病毒癌症疗法

Market Report

市场报告

Oncolytic Virus Cancer Therapy Patient Population Forecast

溶瘤病毒癌症治疗患者人群预测

Oncolytic Virus Cancer Therapy Therapeutics Market Size

溶瘤病毒癌症治疗药物市场规模

Oncolytic Virus Cancer Therapy Pipeline Analysis

溶瘤病毒癌症治疗管线分析

Oncolytic Virus Cancer Therapy Market Size and Trends

溶瘤病毒癌症治疗市场规模与趋势

Oncolytic Virus Cancer Therapy Market Opportunity

溶瘤病毒癌症治疗市场机遇

Oncolytic Virus Cancer Therapy Market Unmet Needs

溶瘤病毒癌症治疗市场的未满足需求

KOL's Views on Oncolytic Virus Cancer Therapy

关键意见领袖对溶瘤病毒癌症疗法的观点

Oncolytic Virus Cancer Therapy Market Access and Reimbursement

溶瘤病毒癌症疗法的市场准入与报销

Discover the oncolytic virus manufacturing analytics @

探索溶瘤病毒制造分析 @

Oncolytic Virus Cancer Therapy Clinical Trials

溶瘤病毒癌症治疗临床试验

Table of Contents

Oncolytic Virus Cancer Therapy Market Key Insights

溶瘤病毒癌症治疗市场关键洞察

Oncolytic Virus Cancer Therapy Market Report Introduction

溶瘤病毒癌症治疗市场报告引言

Executive Summary of Oncolytic Virus Therapies

溶瘤病毒疗法执行摘要

Key Events

关键事件

五

Epidemiology and Market Forecast Methodology

流行病学与市场预测方法论

Oncolytic Virus Therapies Market Overview at a Glance in the 7MM

七国市场溶瘤病毒疗法概览

6.1

Market Share (%) Distribution by Therapies in 2025

2025年按疗法划分的市场份额（%）分布

6.2

Market Share (%) Distribution by Therapies in 2036

2036年按疗法划分的市场份额（%）分布

Background and Overview

背景与概述

7.1

Introduction

简介

7.2

Different Types of Oncolytic Viruses

溶瘤病毒的不同类型

7.3

Application of Oncolytic Viruses

溶瘤病毒的应用

7.4

Multiple Mechanisms of Action of OVTs for Cancer Therapy

溶瘤病毒疗法在癌症治疗中的多种作用机制

7.5

Routes of Administration

给药途径

Epidemiology and Target Patient Pool

流行病学与目标患者群体

8.1

Key Findings

主要发现

8.2

Assumptions and Rationale: 7MM

假设与理由：7MM

8.3

Epidemiology Scenario in the 7MM

七大主要市场（7MM）的流行病学情景

8.3.1

Target Patient Pool of OVTs by Cancer Types in the 7MM

七国市场（7MM）中按癌症类型划分的溶瘤病毒疗法（OVTs）目标患者群体

8.4

The United States

美国

8.4.1

Total Cases of Selected Cancer Types in the United States

美国选定癌症类型的总病例数

8.4.2

Target Patient Pool of OVTs by Cancer Types in the United States

美国按癌症类型划分的溶瘤病毒疗法目标患者群体

8.4.3

Treated Cases by Cancer Types in the United States

美国按癌症类型分类的病例治疗情况

8.5

EU4 and the UK

欧盟四国与英国

8.6

Japan

日本

Marketed Oncolytic Viruses

已上市的溶瘤病毒

9.1

Marketed Competitive Landscape of Oncolytic Virus Cancer Therapy (OVTs)

溶瘤病毒癌症疗法（OVTs）的市场竞争格局

9.2

IMLYGIC (talimogene laherparepvec): Amgen

IMLYGIC（塔利莫金拉赫帕雷普韦克）：安进

9.2.1

Product Description

产品描述

9.2.2

Regulatory Milestones

监管里程碑

9.2.3

Others Developmental Activities

其他发展活动

9.2.4

Ongoing Clinical Developmental Activities

正在进行的临床开发活动

9.2.4.1

Clinical Trial Information

临床试验信息

9.2.5

Safety and Efficacy

安全性与有效性

9.2.6

Analyst Views

分析师观点

9.3

DELYTACT (G47Δ): Daiichi Sankyo

DELYTACT（G47Δ）：第一三共

Emerging Oncolytic Viruses

新兴溶瘤病毒

10.1

Emerging Competitive Landscape of Oncolytic Virus Cancer Therapy (OVTs)

溶瘤病毒癌症疗法（OVTs）新兴的竞争格局

10.2

Olvi-Vec: Genelux

Olvi-Vec：Genelux

10.2.1

Product Description

产品描述

10.2.2

Other Developmental Activity

其他发展活动

10.2.3

Clinical Developmental Activities

临床开发活动

10.2.3.1

Clinical Trial Information

临床试验信息

10.2.4

Safety and Efficacy

安全性与有效性

10.2.5

Analyst Views

分析师观点

10.3

CAN-2409: Candel Therapeutics

CAN-2409：Candel Therapeutics

10.4

RP1: Replimune

RP1：Replimune

10.5

Pelareorep: Oncolytics Biotech

佩拉雷奥普：Oncolytics Biotech

10.6

Cretostimogene grenadenorepvec: CG Oncology

克雷托刺激基因格雷纳多诺雷普韦克：CG肿瘤公司

10.7

CAN-3110: Candel Therapeutics

CAN-3110：Candel Therapeutics

10.8

LoAd703: Lokon Pharma

LoAd703：洛康制药

10.9

CF33: Imugene

CF33：Imugene

List to be continued…

列表待续……

十一

Oncolytic Virus Market: 7MM analysis

溶瘤病毒市场：七大主要市场分析

11.1

Key Findings

主要发现

11.2

Oncolytic Virus Cancer Therapy Market Outlook

溶瘤病毒癌症治疗市场展望

11.3

Conjoint Analysis

联合分析

11.4

Key Oncolytic Virus Cancer Therapy Market Forecast Assumptions

关键溶瘤病毒癌症治疗市场预测假设

11.5

Market Size by Indications in the 7MM

七国市场按适应症划分的市场规模

11.6

Market Size by Therapies in the 7MM

七大主要市场按疗法划分的市场规模

11.7

United States Oncolytic Virus Cancer Therapy Market Size

美国溶瘤病毒癌症治疗市场规模

11.7.1

Market Size by Indications in the US

美国按适应症划分的市场规模

11.7.2

Market Size by Therapies in the US

美国按疗法划分的市场规模

11.8

EU4 and the UK Oncolytic Virus Cancer Therapy Market Size

欧盟四国及英国溶瘤病毒癌症治疗市场规模

11.9

Japan Oncolytic Virus Cancer Therapy Market Size

日本溶瘤病毒癌症治疗市场规模

十二

Unmet Needs

未满足的需求

SWOT Analysis

SWOT分析

KOL Views

KOL观点

十五

Market Access and Reimbursement

市场准入与报销

15.1

United States

美国

15.2

EU4 and the UK

欧盟四国与英国

15.3

Japan

日本

15.4

Summary and Comparison of Market Access and Pricing Policy Developments in 2025

2025年市场准入与定价政策发展综述及比较

15.5

Oncolytic Virus Therapies: Market Access and Reimbursement

溶瘤病毒疗法：市场准入与报销

十六

Bibliography

参考文献

十七

Oncolytic Virus Cancer Therapy Market Report Methodology

溶瘤病毒癌症治疗市场报告方法论

Related Reports

相关报告

Oncolytic Virus Competitive Landscape

溶瘤病毒竞争格局

Oncolytic Virus Competitive Landscape – 2026

溶瘤病毒竞争格局 – 2026

report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key oncolytic virus companies, including

本报告提供关于管线格局、管线药物概况（包括临床和非临床阶段产品）以及关键溶瘤病毒公司的全面洞察，包括

Genelux Corporation, Candel Therapeutics, CG Oncology, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Virogin Biotech, Replimune, Viralytics, Oncolys Biopharma, Istari Oncology, Immvira Pharma, Seneca Therapeutics, Treovir, LLC, Targovax, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, ViruCure, Tasly Pharmaceuticals, Turnstone Biologics, BioInvent, Transgene, Elicera Therapeutics, Orgenesis, Virttu Biologics, Imugene, Astellas Pharma, Wuhan Binhui Biotechnology Co., Ltd., Mustang Bio, Virogin Biotech, Vaxiion Therapeutics, ImmVirX, Memgen, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, VCN Biosciences, Candel therapeutics, Sorrento Therapeutics, Imugene Limited, Calidi Biotherapeutics, Replimune, TILT Biotherapeutics, Guangzhou Virotech Pharmaceutical, DNAtrix, Oncorus, BioEclipse Therapeutics.

Genelux公司、Candel Therapeutics、CG Oncology、DNAtrix、SillaJen Biotherapeutics、Oncolytics Biotech、武汉滨辉生物科技、Oryx GmbH、江苏信诺达生物医药有限公司、Virogin Biotech、Replimune、Viralytics、Oncolys Biopharma、Istari Oncology、Immvira Pharma、Seneca Therapeutics、Treovir, LLC、Targovax、Lokon Pharma、ORCA Therapeutics、北京赛金科技、ViruCure、天士力医药、Turnstone Biologics、BioInvent、Transgene、Elicera Therapeutics、Orgenesis、Virttu Biologics、Imugene、安斯泰来制药、武汉滨辉生物科技有限公司、Mustang Bio、Virogin Biotech、Vaxiion Therapeutics、ImmVirX、Memgen、Replimune、Immvira Pharma、ViroCure、GeneMedicine、PsiOxus Therapeutics、VCN Biosciences、Candel Therapeutics、Sorrento Therapeutics、Imugene Limited、Calidi Biotherapeutics、Replimune、TILT Biotherapeutics、广州唯思康药业、DNAtrix、Oncorus、BioEclipse Therapeutics。

, and others.

，以及其他。

Non-Small Cell Lung Cancer

非小细胞肺癌

Market

市场

Non-Small Cell Lung Cancer

非小细胞肺癌

Market Insights, Epidemiology, and Market Forecast

市场洞察、流行病学及市场预测

–

2036

report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies including

本报告深入解析了该疾病、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和包括以下在内的关键非小细胞肺癌（NSCLC）企业：

BeiGene

百济神州

, Merus and Partner Therapeutics, Johnson & Johnson Innovative Medicine, Betta Pharma, Xcovery, CStone Pharmaceuticals, Bristol-Myers Squibb, Haihe Biopharma, Taiho Pharmaceutical, Takeda Pharmaceuticals, EMD Serono (Merck KGaA), Eli Lilly and Company, Merck, Regeneron, Sanofi, Ono Pharmaceutical, Novartis, Genentech, Roche, Amgen, Chugai Laboratories, Moderna Therapeutics, Pfizer, GSK .

、Merus和Partner Therapeutics、强生创新药物、贝达药业、Xcovery、基石药业、百时美施贵宝、海河生物制药、大正制药、武田制药、EMD Serono（默克KGaA）、礼来公司、默沙东、再生元、赛诺菲、小野制药、诺华、基因泰克、罗氏、安进、中外实验室、Moderna Therapeutics、辉瑞、葛兰素史克。

and others.

以及其他。

Melanoma Market

黑色素瘤市场

Melanoma

黑色素瘤

Market Insights, Epidemiology, and Market Forecast – 2036

市场洞察、流行病学及市场预测 – 2036

report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key melanoma companies including

报告深入解析了该疾病、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和关键黑色素瘤公司，包括

IO Biotech, Merck Sharp & Dohme, Eisai, Regeneron Pharmaceuticals, Iovance Biotherapeutics, Highlight Therapeutics, Linnaeus Therapeutics, Spring Bank Pharmaceuticals, Taiga Biotechnologies, Inc., Aivita Biomedical, Inc., Genentech, Inc., Dana-Farber Cancer Institute, BioMed Valley Discoveries, Inc, Amgen, Checkmate Pharmaceuticals, Astellas Pharma Inc, Galectin Therapeutics Inc., Eucure (Beijing) Biopharma Co., Ltd, Mologen AG, Ultimovacs ASA, Seagen Inc., MedImmune LLC, OnKure, Inc., Syntrix Biosystems, Inc., Anaveon AG, iOx Therapeutics, Portage Biotech, ModernaTX, Inc., Nektar Therapeutics, BioNTech SE, Sapience Therapeutics, HUYABIO International, LLC., Provectus Biopharmaceuticals, Inc., Cantargia AB, Turnstone Biologics, Corp., Aura Biosciences, F-star Therapeutics, Inc., Day One Biopharmaceuticals, Inc., Kinnate Biopharma, Xencor, Inc., HiFiBiO Therapeutics.

IO Biotech、默沙东（Merck Sharp & Dohme）、卫材（Eisai）、再生元制药（Regeneron Pharmaceuticals）、Iovance Biotherapeutics、Highlight Therapeutics、Linnaeus Therapeutics、Spring Bank Pharmaceuticals、Taiga Biotechnologies, Inc.、Aivita Biomedical, Inc.、基因泰克（Genentech, Inc.）、丹娜法伯癌症研究所（Dana-Farber Cancer Institute）、BioMed Valley Discoveries, Inc.、安进（Amgen）、Checkmate Pharmaceuticals、安斯泰来制药（Astellas Pharma Inc.）、Galectin Therapeutics Inc.、欧凯雷（北京）生物科技有限公司（Eucure (Beijing) Biopharma Co., Ltd）、Mologen AG、Ultimovacs ASA、Seagen Inc.、MedImmune LLC、OnKure, Inc.、Syntrix Biosystems, Inc.、Anaveon AG、iOx Therapeutics、Portage Biotech、ModernaTX, Inc.、Nektar Therapeutics、BioNTech SE、Sapience Therapeutics、HUYABIO International, LLC.、Provectus Biopharmaceuticals, Inc.、Cantargia AB、Turnstone Biologics, Corp.、Aura Biosciences、F-star Therapeutics, Inc.、Day One Biopharmaceuticals, Inc.、Kinnate Biopharma、Xencor, Inc.、HiFiBiO Therapeutics。

，

and others.

以及其他。

Pancreatic Cancer Market

胰腺癌市场

Pancreatic Cancer

胰腺癌

Market Insights, Epidemiology, and Market Forecast – 2036

市场洞察、流行病学及市场预测 – 2036年

report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pancreatic cancer companies including

报告提供对疾病的深入理解、历史及预测的流行病学数据，以及市场趋势、市场驱动因素、市场壁垒和关键的胰腺癌公司，包括

FibroGen, OSE Immunotherapeutics, Lokon Pharma, Oncotelic Inc., Tesaro, Inc., Helix BioPharma Corporation, Theradex, Tvardi Therapeutics, Incorporated, AIM ImmunoTech Inc., BioNTech SE, Prestige Biopharma Limited, HCW Biologics, Cantex Pharmaceuticals, XBiotech, Inc., Lumicell, Inc., CARsgen Therapeutics Co., Ltd., Panbela Therapeutics, Inc..

FibroGen、OSE Immunotherapeutics、Lokon Pharma、Oncotelic Inc.、Tesaro, Inc.、Helix BioPharma Corporation、Theradex、Tvardi Therapeutics, Incorporated、AIM ImmunoTech Inc.、BioNTech SE、Prestige Biopharma Limited、HCW Biologics、Cantex Pharmaceuticals、XBiotech, Inc.、Lumicell, Inc.、合源生物技术有限公司（CARsgen Therapeutics Co., Ltd.）、Panbela Therapeutics, Inc.

，

and others.

等等。

About

关于

DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

DelveInsight 是一家领先的商业咨询和市场研究公司，专注于生命科学领域。它通过提供全面的端到端解决方案，帮助制药公司提升绩效。通过我们基于订阅的平台 PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。

。

联系我们

Shruti Thakur

什鲁蒂·塔库尔

[email protected]

+14699457679

SOURCE DelveInsight Business Research, LLP

来源：DelveInsight Business Research, LLP

二十一

百分比

more press release views with